Liu Bixia, Ying Jieer, Luo Cong, Xu Qi, Zhu Liming, Zhong Haijun
Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
Hepatogastroenterology. 2012 Mar-Apr;59(114):649-53. doi: 10.5754/hge11893.
BACKGROUND/AIMS: To evaluate the efficacy and safety profile of S-1 combined with oxaliplatin (SOX) against unresectable advanced or metastatic gastric cancer.
Oxaliplatin was administered intravenously at 100mg/m2 for two hours on day 1 and S-1 was administered b.i.d. at 80mg/m2/day on days 1-14 followed by a 7-day rest during the 3-week schedule.
All 51 patients were assessed for efficacy and adverse events. The response and disease control rates were 41% and 90%, respectively. The response rate was significantly improved in patients with ECOG performance status of no more than 1, elevated CEA levels or unresected primary cancers. The median follow-up time was 11.8 months, the median time to progression was 6.8 months, the median overall survival was 11.8 months and the 1-year survival rate was 47.4%. Patients with diffused type exhibited significantly decreased time to progression and overall survival. The grade 3/4 adverse events were hematological toxicities, including neutropenia (13.7%), thrombocytopenia (13.7%) and anemia (11.8%). The incidence of grade 3/4 non-hematological events was low (≤2%).
The SOX regimen (oxaliplatin, 100mg/m2 d1; S-1, 80mg/m2/day, b.i.d. d1-14, q3w) provided a favorable efficacy and safety profile in Chinese patients with advanced gastric cancer.
背景/目的：评估S-1联合奥沙利铂（SOX）治疗不可切除的晚期或转移性胃癌的疗效和安全性。
奥沙利铂在第1天静脉滴注100mg/m²，持续2小时，S-1在第1 - 14天每日两次，每次80mg/m²，然后在3周疗程中休息7天。
对所有51例患者进行了疗效和不良事件评估。缓解率和疾病控制率分别为41%和90%。在东部肿瘤协作组（ECOG）体能状态不超过1、癌胚抗原（CEA）水平升高或原发癌未切除的患者中，缓解率显著提高。中位随访时间为11.8个月，中位疾病进展时间为6.8个月，中位总生存期为11.8个月，1年生存率为47.4%。弥漫型患者的疾病进展时间和总生存期显著缩短。3/4级不良事件为血液学毒性，包括中性粒细胞减少（13.7%）、血小板减少（13.7%）和贫血（11.8%）。3/4级非血液学事件的发生率较低（≤2%）。
SOX方案（奥沙利铂，100mg/m² d1；S-1，80mg/m²/天，每日两次，d1 - 14，每3周一次）在中国晚期胃癌患者中提供了良好的疗效和安全性。
